GSK2200150A 是一种通过高通量筛选活动确定的抗结核剂，对 H37Rv 的 MIC 是 0.38 μM。

GSK2200150A is an anti-tuberculosis (TB) agent identified by high-throughput screening (HTS) campaign.

GSK2200150A is a novel antimycobacterial agent against Mycobacterium tuberculosis. The activities of GSK2200150A which contains the spirocycle core are determined against the virulent M.tuberculosis strain (H37Rv) with MIC of 0.38 μM [1].

GSK2200150A is tested for activity at either single concentration (100 μM) or serially diluted in 10 μL of purified H2O in triplicate in 96 well microtiter plates. M. tuberculosis H37Rv is grown in complete Middlebrook 7H9 media containing albumin, dextrose and catalase (ADC), 20% Tween 80 and 50% glycerol. A bacterial suspension (90 μL) at OD600 nm of 0.001 is added to the wells and incubated for 7 days. Resazurin (10 μL; 0.05%(w/v)) is then added, incubated for 24 h at 37°C, and fluorescence measured at 590 nm using a FLUOstar Omega microplate reader. After subtraction of background fluorescence from all wells, the percentage mycobacterial survival is determined by comparing the fluorescence of wells containing compounds compared to control wells not treated with compound[1].

1443138-53-1

C20H23NO3S

357.47

DMSO:80 mg/mL
Powder: -20°C for 3 years
In solvent: -80°C for 2 years